Article Text

Download PDFPDF

Short report
Secukinumab does not impair the immunogenic response to the influenza vaccine in patients
  1. Patricia Richi1,2,
  2. María Dolores Martín3,
  3. Fernando de Ory4,
  4. Rosa Gutiérrez-Larraya2,
  5. Inmaculada Casas5,
  6. Ana María Jiménez-Díaz1,
  7. Fernando Cava6 and
  8. Santiago Muñoz-Fernandez1,2
  1. 1Rheumatology Department, Infanta Sofía University Hospital, San Sebastian de los Reyes, Spain
  2. 2School of Medicine, European University of Madrid, Madrid, Spain
  3. 3Bactereology Department, BR Salud Laboratories, San Sebastian de los Reyes, Spain
  4. 4National Microbiology Centre, CIBER-ESP, Instituto de Salud Carlos III, Majadahonda, Spain
  5. 5National Microbiology Centre, Instituto de Salud Carlos III Campus de Majadahonda, Majadahonda, Spain
  6. 6BR Salud Laboratories, San Sebastian de los Reyes, Spain
  1. Correspondence to Dr Patricia Richi; patricia.richi{at}


Objective To evaluate whether immunological response to influenza vaccination is impaired in patients who are receiving secukinumab.

Patients and methods Subjects suffering from psoriatic arthritis or ankylosing spondylitis who were receiving treatment with secukinumab and healthy volunteers were included.

All participants received seasonal inactivated trivalent influenza vaccine recommended by the WHO in the 2017–2018 northern hemisphere influenza season, which contained an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus and a B/Brisbane/60/2008-like virus.

Haemagglutination inhibition was used to evaluate basal antibody (Ab) titres against the three influenza vaccine virus strains just before vaccination and at least 4 weeks after the vaccine administration. Response to vaccine was considered as >4-fold increases in Ab titre.

Results Thirty subjects, 17 patients and 13 healthy controls, with a follow-up duration of 33±8 days, were analysed. There were no demographic differences between groups. Patients and controls achieved a median of 4.6-fold and 4.0-fold increases, respectively, for anti H1N1 and almost 4.0 (3.7) for patients and 5.3 for controls for anti-B Ab. Both groups presented a poor response against H3N2, with <1.5-fold increase. Seroconversion rates were similar in both groups. Secukinumab did not influence the response to the influenza vaccine (relative risk: 1.09 (95% CI 0.58 to 2.07) for H1N1, RR: 1.53 (95% CI 0.15 to 15.0) for H3N2 and RR: 0.72 (95% CI 0.32 to 1.83) for B strain).

Conclusion In our study, secukinumab has no effect on the immunogenic response to the influenza vaccine.

  • vaccination
  • DMARDs (biologic)
  • psoriatic arthritis
  • Ankylosing Spondylitis

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

View Full Text

Statistics from


  • Collaborators Jesús Llorente. Beatriz Paredes.

  • Contributors PR conceived and designed the work, contributed to the acquisition and interpretation of data, and wrote the paper. MDM contributed substantially to the acquisition and analysis of data and drafting of the work. FdO contributed substantially to the acquisition and analysis of data. RG-L contributed substantially to the acquisition and analysis of data and drafting of the paper. IC contributed substantially to the acquisition and analysis of data. AMJ-D contributed substantially to the acquisition of data. FC contributed substantially to the acquisition of data. SM-F contributed substantially to the conception of the work and analysis of data. All authors revised critically the work, approved the final version and agreed on all aspects of the work.

  • Funding The study was approved by La Paz University Hospital Ethic Committee. Approval ID: PI-3076. Data not published is available on request to the corresponding author, Dr PR.

  • Competing interests SM-F declares he has received grants for conference attendance and educational programmes, as well as consultancy payments from Novartis, during the conduct of the study.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement The data that support the findings of this study are available on request from the corresponding author, PR.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.